Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.58 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5008245 | 1.00 | MAPT (0.64) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL2929122 | 0.98 | MAPT (0.66) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL14736626 | 0.86 | MAPT (0.74) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL18158046 | 0.84 | LMNA (0.55) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL855166 | 0.84 | MAPT (0.77) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL1059693 | 0.82 | RAB9A (0.64) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL6000086 | 0.81 | RAB9A (0.58) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL30037937 | 0.81 | RAB9A (0.62) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL757031 | 0.81 | RAB9A (0.62) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL5114083 | 0.81 | MAPT (0.88) | MAPTRAB9ANPC1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472543-B2 | Waste disposal system and waste receiver for receiving and disposing of pharmaceutical waste material | STRYKER CORPORATION (US) | 2025-11-18 | — | — | US | disclosed |
| US-12434282-B2 | Pharmaceutical waste system | STRYKER CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250268679-A1 | Waster Receiver For Receiving A Pharmaceutical Waste Material | STRYKER CORPORATION (US) | 2025-08-28 | — | — | US | disclosed |
| US-12318823-B2 | Waste receiver for receiving a pharmaceutical waste material | STRYKER CORPORATION (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250144680-A1 | Pharmaceutical Waste Disposal Assembly | STRYKER CORPORATION (US) | 2025-05-08 | — | — | US | disclosed |
| EP-3902638-B1 | METHOD OF DISPOSING OF WASTE RECEIVER AND WASTE RECEIVER FOR PHARMACEUTICAL WASTE | STRYKER CORP (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12194516-B2 | Pharmaceutical waste disposal assembly | STRYKER CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240359222-A1 | Waste Receiver For Receiving A Pharmaceutical Waste Material | STRYKER CORPORATION (US) | 2024-10-31 | — | — | US | disclosed |
| US-12064797-B2 | Method of disposing of waste receiver, waste receiver for pharmaceutical waste and method of assembling the waste receiver | STRYKER CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240066574-A1 | Waste Disposal System And Waste Receiver For Receiving And Disposing Of Pharmaceutical Waste Material | STRYKER CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| EP-1135374-B9 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1135374-B1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2006-07-20 | — | — | US | disclosed |
| US-7053107-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1585743-A1 | 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | PFIZER INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004056806-A1 | 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES | PFIZER INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| EP-1135374-A1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6204282-B1 | TREATING CANCER, RETINOPATHY, ATHEROSCLEROSIS, VASCULAR RESTENOSIS, OR OSTEOPOROSIS. | SCHERING CORPORATION | 2001-03-20 | — | — | US | disclosed |
| WO-2000032578-A1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | GAA 2287/4885HDAC6 966/4885MAPT 921/4885 |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | GAA 2287/4885HDAC6 966/4885MAPT 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.